



AMENDMENTS IN THE CLAIMS



This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims

1. (currently amended) A compound according to formula (I):



or a pharmaceutically acceptable salt, solvate, or polymorph thereof, wherein R¹ is H or a C₁-C₄ alkyl group;



O
||

R³ is H, a C₁-C₂₀ alkyl group, an OR group, an alkylene ester group -(CH₂)_nC-OR¹⁰, an amine group -NR¹¹R¹² or a ~~-(CH₂)_m-group~~ ~~-(CH₂)_m-group~~ where m is 1-3 and forms a ring with R⁶, R is a C₁-C₂₀ alkyl group, an aryl group or an alkylene aryl group, R¹⁰ is a C₁-C₁₀ alkyl group, n is 1 to 20, R¹¹ is selected from H, C₁-C₄ alkyl, aryl, alkylene aryl or an alkylene ester group as described above, and R¹² is selected from H, C₁-C₄ alkyl, aryl, alkylene aryl or an alkylene ester group as described above or is a -(CH₂)_z-group where z is 0 to 2, such that R¹² forms a ring with R⁶, and wherein when one of R¹¹ and R¹² is other than H, the other of R¹¹ or R¹² is H; R⁶ is H, C₁-C₄ alkyl, F, Cl, Br, I, NO₂ or a NR¹³R¹⁴ group where R¹³ is H or a C₁-C₃ alkyl group and R¹⁴ is a -(CH₂)_m- group where m is 0 to 3 and forms a ring with the

O
||

~~-C-R³ group when R³-is absent; and each of R⁷, R⁸ and R⁹~~ R⁷, R⁸ and R⁹ is independently selected from H, C₁-C₄ alkyl, F, Cl, Br, I or NO₂, ~~preferably, at least two, and more preferably three of R⁷, R⁸ and R⁹ are H.~~

2. (currently amended) A The compound of claim 1, ~~or a pharmaceutically acceptable salt, solvate, or polymorph thereof,~~ selected from the group consisting of:

N - (4-Pyridyl) *t*-Butyl Carbamate;
N - (4-Pyridyl) Ethyl Carbamate;
N - (4-Pyridyl) Methyl Carbamate;
N - (4-Pyridyl) Isopropyl Carbamate;
N - (4-Pyridyl) Dodecyl Carbamate;
N - (4-Pyridyl) Benzyl Carbamate;
N - (4-Pyridyl) Benzamide;
N - (4-Pyridyl) Acetamide;
N - (4-Pyridyl) Propionamide;
N - (4-Pyridyl) Trimethylacetamide;

N - (4-Pyridyl) Ethyl Succinamate;
N, *N*'- (4-Pyridyl) Urea;
N, *N*'- (3,4-Pyridyl) Urea;
P, *P*-Diphenyl *N*- (4-Pyridyl) Phosphinamide; and
4-Pyridinyl Phosphoramidic acid, Diphenyl Ester; and
a pharmaceutically acceptable salt, solvate, or polymorph thereof.

3. (currently amended) A pharmaceutical composition for the treatment of injured mammalian nerve tissue, comprising a pharmaceutically acceptable carrier and an effective amount of a compound of claim 1, or a pharmaceutically acceptable salt, solvate, or polymorph thereof; ~~effective in such treatment.~~

4. (currently amended) ~~A~~ The pharmaceutical composition of claim 3, wherein the compound ~~of claim 1~~ is selected from the group consisting of:

N - (4-Pyridyl) *t*-Butyl Carbamate;
N - (4-Pyridyl) Ethyl Carbamate;
N - (4-Pyridyl) Methyl Carbamate;
N - (4-Pyridyl) Isopropyl Carbamate;
N - (4-Pyridyl) Dodecyl Carbamate;
N - (4-Pyridyl) Benzyl Carbamate;
N - (4-Pyridyl) Benzamide;
N - (4-Pyridyl) Acetamide;
N - (4-Pyridyl) Propionamide;
N - (4-Pyridyl) Trimethylacetamide;
N - (4-Pyridyl) Ethyl Succinamate;
N, *N*'- (4-Pyridyl) Urea;
N, *N*'- (3,4-Pyridyl) Urea;
P, *P*-Diphenyl *N*- (4-Pyridyl) Phosphinamide; and
4-Pyridinyl Phosphoramidic acid, Diphenyl Ester;
and the pharmaceutically acceptable salts, solvates, and polymorphs thereof.

5. Cancelled

6. Cancelled

7. Cancelled

8. Cancelled

9. Cancelled

10. Cancelled

11. Cancelled

12. Cancelled

13. Cancelled

14. Cancelled

15. (New) The compound of claim 1, wherein R^1 , R^6 , R^7 , R^8 and R^9 are each H; and R^2 is a $-C(O)R^3$ group, wherein R^3 is $-OCH_2CH_3$.